Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today we highlight:
- an article in response to “the confirmation hearing last week for John Squires” that discussed “the complex intersection between patent quality, patent examination and the Patent Trial and Appeal Board”;
- a blog post indicating that, “[i]n a number of recent opinions, the Federal Circuit decided the case on grounds that were not raised on appeal by either party”;
- a piece detailing how “Amgen Inc’s ongoing challenge to a Colorado Law regulating retail drug prices could serve as a litmus test for widespread state government efforts to keep medication costs low;” and
- a report covering how VLSI Technology LLC’s connection to Fortress Investment Group “will be at the heart of a three-day trial” next week that “could upend infringement verdicts against Intel Corp. totaling more than $3 billion.”